Circular Genomics Receives $250K Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance First-in-Class Circular RNA Blood-Based Biomarker Tests for the Early Detection of Alzheimer’s Disease Share: Facebook Twitter LinkedIn